DNA Script Enables Same-day q/dPCR from Design to Results with Launch of Next-generation SYNTAX Kits at AGBT
6.6.2022 15:00:00 EEST | Business Wire | Press release
Today at the Advances in Genome Biology and Technology (AGBT) Conference, DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, announced the launch of the industry’s first solution to enable same-day turnaround for custom q/dPCR assays with a new generation of kits for the SYNTAX System to print both primers and probes in hours. This announcement comes two days ahead of their AGBT presentation on Wed, June 8, at 2:55pm EDT, where their founders will review recent data showcasing the new applications enabled for the SYNTAX System.
For the first time since the introduction of PCR in 1984, labs will be able to design and print q/dPCR assays, directly on their benchtops, in as little as 8 hours. The combination of increased performance, just 15 minutes of set up, rapid synthesis turnaround and complete workflow control provides labs the best value for custom modified oligos. The new kits are designed to accelerate assay development workflows in genomics, in particular for q/dPCR, NGS, ISH and FISH.
“We see this product launch as a game-changer, enabling SYNTAX customers to be done with their assays before others have even started. More than ever before, science and innovation are in a race for results, whether it is an upcoming scientific publication, a new diagnostic test or even a vaccine. Researchers need to get there faster, and we will help them to get there first,” said DNA Script CEO and co-founder Thomas Ybert, Ph.D. “With an in-house, benchtop SYNTAX System and these new kits, we are enabling our customers to replace a complex synthesis workflow with a single instrument that takes the iterative assay development process from months down to days.”
This latest generation of kits launches several new capabilities on the SYNTAX Platform:
- Print oligos up to 80 nt in length
- Synthesize hydrolysis probes and primers in the same run, in as little as 8 hours
- Print oligos at a higher yield and concentration (≥7 µM and ≥600 pmol)
- Label probes with fluorophores, quenchers and biotin
DNA Script’s SYNTAX Platform offers researchers dramatic time savings, printing primers and probes in 8 - 12 hours, as well as the best value per assay compared to leading third-party oligo service solutions in the marketplace. Early adopters of the SYNTAX platform have already leveraged on-demand synthesis to eliminate bottlenecks in the development of assays for biothreat detection, assays for rapid-response to viral outbreaks, and novel vaccines and therapies.
“The SYNTAX System is a game changer for preclinical CRO labs like ours. For the biomarker identification and gene expression profiling we do, we spend thousands of dollars a month on primers and probes and end up waiting for them to be synthesized and shipped. Having SYNTAX on site cuts our assay turnaround time, decreases our cost per assay by ~30%, and enables our lab to optimize expression assays more quickly--all of which significantly improves our bottom line," said Jonathan Wray, Managing Partner at DC3 Therapeutics. “The ease of use and excellent service and support from DNA Script enabled us to be up and running with the SYNTAX System in no time.”
As a Bronze sponsor, DNA Script is hosting a hospitality room in the Jade-Lexington Suite throughout the duration of the AGBT Conference, where attendees can see the SYNTAX System in action, demonstrating the speed of synthesizing probes and primers in-house with plug-and-play ease and automation. One-on-one demonstrations can be scheduled in advance.
DNA Script presentations at AGBT include:
-
Podium Presentation: Same-Day Enzymatic DNA Synthesis: Now Print Primers and Labeled Probes Using the SYNTAX System
Presenters: Ybert and DNA Script CTO and co-founder Xavier Godron, Ph.D.
Date & Time: Wed, June 8, 2:55 - 3:15 pm EDT
Location: Main Session - Floridian Salons A-L -
Poster Presentation (#517): Enzymatic DNA Synthesis (EDS) Allows Rapid Access to Synthetic Oligos to Produce Expression Vectors for SARS-CoV-2 Spike Variants
Presenters: Benoit Derrien, Ph.D., Application Project Leader, DNA Script
Date & Time: Tues, June 7, 1:30 - 3:00 pm EDT
Location: Bonnet Creek Ballroom Salon VII-XII -
Poster Presentation (#540): Access to Synthetic Oligos Produced by Enzymatic DNA Synthesis (EDS) Accelerated the Development of Candida glabrata Mutants During the COVID-19 Pandemic
Presenters: Colin Clairet, Ph.D., Post-doctoral Researcher, Institut Pasteur
Date & Time: Wed, June 8, 4:40 pm - 6:10 pm EDT
Location: Bonnet Creek Ballroom Salon VII-XII
“Since we released the world’s first commercial access to Enzymatic DNA Synthesis via the SYNTAX Platform in the summer of 2021, we have made a number of improvements to advance benchtop DNA printing,” said Ybert. “Given the many applications, and the urgent need to perform them quickly, in-house DNA printing on demand is becoming one of the most important technologies of the 21st century.”
About DNA Script
Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, enabling this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy. www.dnascript.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005238/en/
Contact information
Press contacts in the US
Seismic
Valerie Enes
415-692-6799
valerie@teamseismic.com
DNA Script Contact
Joleen Rau
joleen.rau@dnascript.co
publicrelations@dnascript.co
Press contact in Europe
ALIZE RP
Caroline Carmagnol
06 64 18 99 59
caroline@alizerp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
